[HTML][HTML] Chemohormonal therapy in metastatic hormone-sensitive prostate cancer

…, M Hussain, JA Garcia, RS DiPaola - … England Journal of …, 2015 - Mass Medical Soc
Background Androgen-deprivation therapy (ADT) has been the backbone of treatment for
metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with …

[HTML][HTML] Autophagy suppresses tumorigenesis through elimination of p62

…, K Bray, A Reddy, G Bhanot, C Gelinas, RS DiPaola… - Cell, 2009 - cell.com
Allelic loss of the essential autophagy gene beclin1 occurs in human cancers and renders
mice tumor-prone suggesting that autophagy is a tumor-suppression mechanism. While tumor …

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

…, V Karantza, HA Coller, RS DiPaola… - Genes & …, 2011 - genesdev.cshlp.org
Autophagy is a catabolic pathway used by cells to support metabolism in response to starvation
and to clear damaged proteins and organelles in response to stress. We report here that …

The double-edged sword of autophagy modulation in cancer

E White, RS DiPaola - Clinical cancer research, 2009 - AACR
Macroautophagy (autophagy) is a lysosomal degradation pathway for the breakdown of
intracellular proteins and organelles. Although constitutive autophagy is a homeostatic …

Principles and current strategies for targeting autophagy for cancer treatment

…, WA Weiss, N Takebe, W Timmer, RS DiPaola… - Clinical cancer …, 2011 - AACR
Autophagy is an evolutionarily conserved, intracellular self-defense mechanism in which
organelles and proteins are sequestered into autophagic vesicles that are subsequently …

[HTML][HTML] Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial

…, MM Cooney, JA Garcia, RS DiPaola… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the
longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we …

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

…, W Stadler, M Carducci, R Coomes, RS DiPaola - The Lancet, 2016 - thelancet.com
Background Renal-cell carcinoma is highly vascular, and proliferates primarily through
dysregulation of the vascular endothelial growth factor (VEGF) pathway. We tested sunitinib and …

Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis

…, E Snyder, U Santanam, RS DiPaola… - Genes & …, 2013 - genesdev.cshlp.org
Macroautophagy (autophagy hereafter) degrades and recycles proteins and organelles to
support metabolism and survival in starvation. Oncogenic Ras up-regulates autophagy, and …

Outcomes of localized prostate cancer following conservative management

…, PC Albertsen, DF Moore, W Shih, Y Lin, RS DiPaola… - Jama, 2009 - jamanetwork.com
Context Most newly diagnosed prostate cancers are clinically localized, and major treatment
options include surgery, radiation, or conservative management. Although conservative …

A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

…, AD Ricart, EG Chiorean, RS DiPaola… - Cancer chemotherapy …, 2013 - Springer
Purpose This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and
maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-d-glucose (2DG) in …